Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

High-cost Gilead cell therapy proves durable for some lymphoma patients

Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc.’s Yescarta were still responding to the cell therapy after at least two years of follow-up.

Read More »

FDA approves first biosimilar to Roche cancer drug Rituxan

Celltrion Inc.’s Truxima became the first biosimilar to Roche Holding AG’s $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin’s lymphoma.

Read More »

Affimed puts on hold cancer drug trial after patient death

Affimed N.V. put on hold the testing of the drug developer’s experimental cancer drug following the death of a patient and two life-threatening events.

Read More »

Study Shows Drugs on FDA Shortage List Are Likely to See Price Hikes

According to a drug shortage list provided by the U.S. Food and Drug Administration, there have been more than 100 drugs that have faced shortages during 2018.

Read More »

Bayer Cutting More Than 200 Jobs in San Francisco Bay Area

German company Bayer AG is laying off 227 staffers at the company’s manufacturing plant in Berkeley, California. Most of the cuts took place on October 3, 2018.

Read More »

R&D Cooperation Between China and Western Pharma Companies Up 70 Percent

China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates, and western pharmaceutical companies are making greater inroads there.

Read More »

UK rejects Gilead’s CAR-T cancer cell therapy as too expensive

A cutting-edge CAR-T cell therapy for otherwise untreatable forms of blood cancer is too expensive to justify its use on Britain’s state-funded health service, the country’s healthcare cost agency NICE said.

Read More »

U.S. FDA Approves Imbruvica For Rare Blood Cancer

The Janssen Pharmaceutical Companies of J&J announced the U.S. FDA approval of Imbruvica (ibrutinib) in combination with rituximab for the treatment of Waldenström’s macroglobulinemia.

Read More »

Celgene Reports Promising Data For Revlimid-Rituximab Combination For Relapsed/Refractory Indolent Lymphoma

Celgene Corporation announced results from a phase III, randomized, double-blind, international clinical study AUGMENT showing that Revlimid (lenalidomide) plus rituximab (R2) achieved a highly statistically significant improvement in the primary endpoint of progression-free survival compared to rituximab plus placebo, in the final PFS analysis.

Read More »

BeiGene To Pursue U.S. Accelerated Approval Of Zanubrutinib In Waldenström Macroglobulinemia

BeiGene Ltd. announced that the commercial-stage biopharmaceutical company’s investigational BTK inhibitor zanubrutinib was granted Fast Track designation by the U.S. FDA for the treatment of patients with Waldenström macroglobulinemia.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom